IAG 933, a potent inhibitor of the interaction between TEAD and the YAP/TAZ complex, is under testing in a phase I trial that is currently enrolling mesothelioma patients or patients with known NF2-inactivating mutations (NCT04857372). Here, NF2 is linked to mesothelioma.